Compare SEVN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEVN | IMUX |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9M | 155.8M |
| IPO Year | 2008 | 2013 |
| Metric | SEVN | IMUX |
|---|---|---|
| Price | $6.17 | $7.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $9.55 | ★ $43.09 |
| AVG Volume (30 Days) | 196.9K | ★ 382.7K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 18.15% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $18.67 | N/A |
| Revenue Next Year | $12.98 | N/A |
| P/E Ratio | $32.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $0.51 |
| 52 Week High | $10.61 | $17.43 |
| Indicator | SEVN | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 27.57 | 36.21 |
| Support Level | N/A | $6.35 |
| Resistance Level | $8.84 | $8.60 |
| Average True Range (ATR) | 0.20 | 0.65 |
| MACD | -0.06 | 0.19 |
| Stochastic Oscillator | 17.76 | 46.67 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.